1stOncology™: Cancer Intelligence Service – Page 14763 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

MacroGenics to Present at the 36th Annual J.P. Morgan Healthcare Conference

On January 4, 2018 MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, reported that Scott Koenig, M.D., Ph.D., President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 11, 2018 at 11:00 a.m. PT (2:00 p.m. ET) (Press release, MacroGenics, JAN 4, 2018, View Source [SID1234522910]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A webcast of MacroGenics’ presentation may be accessed under "Events & Presentations" in the Investor Relations section of the Company’s website at View Source The Company will maintain an archived replay of the webcast on its website for 30 days after the conference.

Cellectar Biosciences to Participate at Biotech Showcase 2018

On January 4, 2018 Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported that company management will be participating in Biotech Showcase 2018 taking place January 8-10, 2018 at the Hilton San Francisco Union Square (Press release, Cellectar Biosciences, JAN 4, 2018, View Source [SID1234522906]). James Caruso, president and chief executive officer of Cellectar Biosciences, will present a company overview and update on January 10, 2018 at 10:00 a.m. Pacific time.

Mr. Caruso’s presentation will be webcast live at View Source;tp_key=5c62464b98 and on the Events section of the company’s website where it will also be archived.

About Phospholipid Drug Conjugates (PDCs)

Cellectar’s product candidates are built upon its patented cancer cell-targeting delivery and retention platform of optimized phospholipid ether-drug conjugates (PDCs). The company deliberately designed its phospholipid ether (PLE) carrier platform to be coupled with a variety of payloads to facilitate both therapeutic and diagnostic applications. The basis for selective tumor targeting of our PDC compounds lies in the differences between the plasma membranes of cancer cells compared to those of normal cells. Cancer cell membranes are highly enriched in lipid rafts, which are glycolipoprotein microdomains of the plasma membrane of cells that contain high concentrations of cholesterol and sphingolipids, and serve to organize cell surface and intracellular signaling molecules. PDCs have been tested in more than 80 different xenograft models of cancer.

Atara Biotherapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

On January 4, 2018 Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, reported that Isaac Ciechanover, M.D., the Company’s President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018, at 3:30 p.m. PST (Press release, Atara Biotherapeutics, JAN 4, 2018, View Source [SID1234522904]). The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.

A live webcast of the presentation will be available by visiting the Investors section of the Atara website at www.atarabio.com. An archived replay of the webcast will be available on the Company’s website for 14 days following the presentation.

Amgen To Present At The 36th Annual J.P. Morgan Healthcare Conference

On January 4, 2018 Amgen (NASDAQ: AMGN) reported that it will present at the 36th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 9, 2018, in San Francisco (Press release, Amgen, JAN 4, 2018, View Source;p=RssLanding&cat=news&id=2324978 [SID1234522903]). Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen’s website for at least 90 days following the event.

Aduro Biotech to Present at the 36th Annual J.P. Morgan Healthcare Conference

On January 4, 2018 Aduro Biotech, Inc. (NASDAQ:ADRO) reported that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 36TH Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11, 2018, at 9:00 am Pacific Time (Press release, Aduro Biotech, JAN 4, 2018, View Source;p=RssLanding&cat=news&id=2324984 [SID1234522902]).

To access the live webcast and subsequent archived recording of this and other company presentations, please visit Aduro’s website at www.aduro.com.